Literature DB >> 15004565

Differential quantitative analysis of MHC ligands by mass spectrometry using stable isotope labeling.

Claudia Lemmel, Steffen Weik, Ute Eberle, Jörn Dengjel, Thomas Kratt, Horst-Dieter Becker, Hans-Georg Rammensee, Stefan Stevanovic.   

Abstract

Currently, no method allows direct and quantitative comparison of MHC-presented peptides in pairs of samples, such as transfected and untransfected, tumorous and normal or infected and uninfected tissues or cell lines. Here we introduce two approaches that use isotopically labeled reagents to quantify by mass spectrometry the ratio of peptides from each source. The first method involves acetylation and is both fast and simple. However, higher peptide recoveries and a finer sensitivity are achieved by the second method, which combines guanidination and nicotinylation, because the charge state of peptides can be maintained. Using differential acetylation, we identified a beta catenin-derived peptide in solid colon carcinoma overpresented on human leucocyte antigen-A (HLA-A)(*)6801. Guanidination/nicotinylation was applied to keratin 18-transfected cells and resulted in the characterization of the peptide RLASYLDRV (HLA-A(*)0201), exclusively presented on the transfectant. Thus, we demonstrate methods that enable a pairwise quantitative comparison leading to the identification of overpresented MHC ligands.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15004565     DOI: 10.1038/nbt947

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  25 in total

1.  Residue 81 confers a restricted C-terminal peptide binding motif in HLA-B*44:09.

Authors:  Trevor Huyton; Heike Schumacher; Rainer Blasczyk; Christina Bade-Doeding
Journal:  Immunogenetics       Date:  2012-06-16       Impact factor: 2.846

2.  The contributions of mass spectrometry to understanding of immune recognition by T lymphocytes.

Authors:  Victor H Engelhard
Journal:  Int J Mass Spectrom       Date:  2007-01-01       Impact factor: 1.986

3.  N (α) Selective Acetylation of Peptides.

Authors:  Toshiyuki Mikami; Toshifumi Takao; Kazunori Yanagi; Hiroshi Nakazawa
Journal:  Mass Spectrom (Tokyo)       Date:  2012-11-07

Review 4.  Mapping the tumour human leukocyte antigen (HLA) ligandome by mass spectrometry.

Authors:  Lena Katharina Freudenmann; Ana Marcu; Stefan Stevanović
Journal:  Immunology       Date:  2018-05-08       Impact factor: 7.397

Review 5.  Insights into MHC class I antigen processing gained from large-scale analysis of class I ligands.

Authors:  Gabor Mester; Vanessa Hoffmann; Stefan Stevanović
Journal:  Cell Mol Life Sci       Date:  2011-03-09       Impact factor: 9.261

6.  Guidance Document: Validation of a High-Performance Liquid Chromatography-Tandem Mass Spectrometry Immunopeptidomics Assay for the Identification of HLA Class I Ligands Suitable for Pharmaceutical Therapies.

Authors:  Michael Ghosh; Marion Gauger; Ana Marcu; Annika Nelde; Monika Denk; Heiko Schuster; Hans-Georg Rammensee; Stefan Stevanović
Journal:  Mol Cell Proteomics       Date:  2020-01-14       Impact factor: 5.911

7.  Multiplexed Relative Quantitation with Isobaric Tagging Mass Spectrometry Reveals Class I Major Histocompatibility Complex Ligand Dynamics in Response to Doxorubicin.

Authors:  J Patrick Murphy; Qijia Yu; Prathyusha Konda; Joao A Paulo; Mark P Jedrychowski; Daniel J Kowalewski; Heiko Schuster; Youra Kim; Derek Clements; Aditya Jain; Stefan Stevanovic; Steven P Gygi; Joseph D Mancias; Shashi Gujar
Journal:  Anal Chem       Date:  2019-02-22       Impact factor: 6.986

Review 8.  MHC class I antigen presentation and implications for developing a new generation of therapeutic vaccines.

Authors:  Joseph D Comber; Ramila Philip
Journal:  Ther Adv Vaccines       Date:  2014-05

9.  Guanidination of tryptic peptides without desalting for matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry analysis.

Authors:  Margaret R Baker; Qing X Li
Journal:  Anal Chem       Date:  2013-09-05       Impact factor: 6.986

Review 10.  Cancer proteomics by quantitative shotgun proteomics.

Authors:  Emily I Chen; John R Yates
Journal:  Mol Oncol       Date:  2007-09       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.